

# Viread® Registration In The Developing World

## Approved

1. Argentina	December 2003	25. Georgia	September 2009	49. Panama	June 2010
2. Armenia	October 2008	26. Ghana	July 2005	50. Paraguay	November 2009
3. Aruba	July 2011	27. Guatemala	September 2008	51. Peru	August 2008
4. Azerbaijan	May 2009	28. Guinea	March 2007	52. Philippines	March 2014
5. Bangladesh	April 2010	29. Guyana	December 2008	53. Senegal	February 2008
6. Benin	April 2010	30. Honduras	July 2008	54. Sint Maarten	June 2016
7. Bolivia	November 2009	31. Ivory Coast	January 2012	55. South Africa	April 2007
8. Botswana	June 2005	32. Jamaica	January 2009	56. Tanzania	September 2007
9. Brazil	June 2003	33. Kazakhstan	February 2011	57. Thailand	August 2006
10. Burkina Faso	April 2008	34. Kenya	January 2005	58. Togo	June 2007
11. Cameroon	February 2009	35. Kyrgyzstan	January 2011	59. Trinidad & Tobago	April 2008
12. Central African Republic	March 2008	36. Madagascar	October 2017	60. Turkmenistan	February 2009
13. Chad	February 2012	37. Malawi	May 2007	61. Uganda	September 2005
14. Chile	September 2006	38. Mali	March 2008	62. Ukraine	May 2008
15. Colombia	July 2010	39. Mauritania	July 2007	63. Uruguay	January 2006
16. Congo, Dem. Rep. of the	August 2015	40. Mauritius	April 2006	64. Uzbekistan	December 2009
17. Congo, Rep. of the	April 2008	41. Mexico	August 2004	65. Venezuela	February 2014
18. Costa Rica	May 2011	42. Moldova	December 2007	66. Zambia	September 2006
19. Curacao	September 2009	43. Mongolia	September 2014	67. Zimbabwe	June 2009
20. Dominican Republic	April 2016	44. Mozambique	April 2009		
21. Egypt	March 2012	45. Namibia	July 2005		
22. El Salvador	December 2008	46. Niger	January 2008		
23. Ethiopia	July 2006	47. Nigeria	August 2006		
24. Gabon	March 2007	48. Pakistan	January 2013		

## Terms and Definitions

**Approved:** Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

**Filed:** Dossier submitted and review pending.

## Note

There can be no guarantee that marketing approval for Viread® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.